Clinical Trial Update: Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia [EARLY_Phase 1]

View source ↗

Summary

Early-phase clinical trial of allogeneic CD19-targeted CAR-γδT cell infusion therapy for relapsed/refractory B-cell acute lymphoblastic leukemia is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Allogeneic CD19-targeted CAR-γδT cell infusion therapy (CAR-γδT cell therapy targeting CD19)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: B-Cell Acute Lymphoblastic Leukemia, Adult | EARLY_Phase 1 | Status: RECRUITING